期刊文献+

p53和表皮生长因子受体在胃癌中的表达及其临床病理意义 被引量:5

Expression and its clinical significance of p53 and Epidermal growth factor receptor (EGFR)in gastric cancer
下载PDF
导出
摘要 目的探讨p53和表皮生长因子受体(Epidermal growth factor receptor,EGFR)在胃癌中的表达及其临床病理意义。方法采用免疫组化PV-6000法检测45例正常胃黏膜、320例胃癌组织中p53和EGFR的表达。结果p53、EGFR在320例胃癌中的阳性表达明显高于正常胃黏膜组织,两者之间有统计学差异(P〈0.01)。320例胃癌组织中,p53的阳性表达与胃癌组织的分化程度、浸润深度及淋巴结转移有关(P〈0.05),而与患者的年龄、性别、肿块的大小及组织学类型无关;320例胃癌中EGFR的阳性表达与肿块大小、组织分化程度、浸润深度及淋巴结转移有关(P〈0.05),而与患者的年龄、性别及组织学类型无关。结论p53和EGFR在胃癌的发生、发展过程中发挥了一定的作用,检测两者在胃癌中的表达有助于预测患者的预后,并为临床进行靶向治疗提供依据。 Objective To investigale the expression and its clinical significance of p53 and EGFR in gastric cancer. Methods The expressions of p53 and EGFR were detected in 45 cases normal gastric mucosa and 320 cases of gastric cancer by immunohistochemistry of PV - 6000. Results The positive expression rates of P53 and EGFR in 320 cases of gastric cancer were significantly higher than those in normal gastric mucosa. There were statistically significant between the tissues of normal gastric mucosa and gastric cancer( P 〈 0.01 ). In 320 cases of gastric cancer, p53 protein expression was related to gastric cancer differentiation, stomach infiltration depth and lymph node metastasis. The expression of EGFR was related to gastric cancer differentiation, tumor size, stomach infiltration depth and lymph node metastasis. Conclusion p53 and EGFR play a certain role in the development, progression of gastric cancer. The experiment may provide a theoretical foundation for clinical therapy of gastric cancer.
出处 《实用肿瘤学杂志》 CAS 2012年第6期532-536,共5页 Practical Oncology Journal
关键词 P53 表皮生长因子受体 胃癌 免疫组织化学 p53 EGFR Gastric cancer Immunohistochemistry
  • 相关文献

参考文献10

二级参考文献37

共引文献43

同被引文献108

  • 1冯莉,刘巍,洪雷,吕雅蕾,王玉栋,左静,王龙,韩晶,单玉洁.化疗联合局部热疗治疗晚期胃癌疗效与安全性的Meta分析[J].转化医学杂志,2014,3(2):84-87. 被引量:7
  • 2亓久德,玄菲,任刚,郭本成.全身热疗联合化疗治疗晚期胃癌17例疗效观察[J].山东医药,2007,47(2):58-58. 被引量:3
  • 3Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin,2011,61(2) :69 -90.
  • 4Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [J]. CA Cancer J Clin,2012,62(1) :10 -29.
  • 5Bang YJ,Van Cutsem E,Feyereislova A,et al. Trastuzumab in combination with chemotherapy versus chemotherapy a- lone for treatment of Her - 2 - positive advanced gastc orgastro - oesophageal junction cancer ( ToGA ) : a phase 3, open - label, randomised controlled trim [ J ]. Lancet, 2010, 376 (9742) :687 - 697.
  • 6Smith I,Procter M,C, elber RD,et al. 2 - year follow - up of trastuzumab after adjuvant chemotherapy in Her - 2 - posi- tive breast cancer: a randomlsed controlled trial[ J]. Lancet, 2007,369(9555) :29 - 36.
  • 7Ruschoff J, etel M, Beon G, et al. Her - 2 diagnostics in gastric cancer- guideline validation and development of standardized innnunohistochemical testing [ J ]. Virchows Arch,2010,457 ( 3 ) : 299 - 307.
  • 8Tai W,Mahato R,Cheng K. The role of Her -2 in cancer therapy and targeted drug delivery[ J ]. J Control Release, 2010,146(3) :264 -275,.
  • 9Hendriks BS,Orr G,WeUs A,et al. Parsing ERK activation reveals quantitatively equivalent contributions from epider- mal growth factor receptor and Her - 2 in human mammary epithelial ceils[ J]. J Bid Chem,2005,280 (7) :6157 - 6169.
  • 10Rubin I, Yarden Y, The basic biology of Her - 2 [ J ]. Ann 0ncol,2001,12 ( Suppl 1 ) : $3 - 8,.

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部